JUVE-BASIS Baricitinib in JIA Phase 3 RCT wk12 Cs or BioDMARDs IR ⚡️Time to disease flare HR 0.24 ⚡️JIA-ACR50% 63% ⚡️% flares 17% vs. 50% in PBO Safety profile similar than adults @RheumNow #EULAR2022 LB0002 https://t.co/dX3DpB4QHT

@EricFMorand up first in late-breakings PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean Good outcomes: primary: SRI(4) at 32w skin/joint/LLDAS & dsDNA/C4 Safety good (like PsO/PsA) but higher dose less so Watch for: other clinical, ph3 #EULAR2022 @RheumNow https://t.co/XOQWuiHkTx

#POS1207 #EULAR2022 In N=98 RA patients with poor antibody response to rituximab after two doses, 19% responded after 3rd dose. Associated with longer Time of vaccine from last RTX & interestingly ultra dose 200mg used in the Netherlands @RheumNow https://t.co/TTXXtOU6vp

#EULAR2022 LB0001 Bimekizumab (IL-17F and IL-17A) in bionaive PsA BE OPTIMAL phase 3 trial, 24 weeks ⭐️Met Primary endpt - ACR50 ⭐️Met other ACR and PASI endpts ⭐️Safety: higher fungal infections @RheumNow https://t.co/x8u6B93FNl

Who remotely enters PROs online? Glintborg et al from the Danbio Registry showed that patients who used the system were mainly 40-80 years of age, on biologics and had lower HAQ score. Disease duration and diagnosis had no impact, reminders helped #EULAR2022 @RheumNow POS0373 https://t.co/voCfGiJgwm

Fascinating! Richette et al. Machine learning identifies 8 clusters of PsA phenotypes. Treatment responses seem to differ, being better in cluster 2 and worse in cluster 5 and 6 (at least for IL23i guselkumab). @RheumNow #EULAR2022 POS1055 https://t.co/QIh2SbJKpa

Magrey et al. IL23i Risankizumab improves enthesitis in PsA @RheumNow #EULAR2022 POS1057 https://t.co/BjuYj6xUdZ

Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT

#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq

BRIDGE-PMR (rituximab in PMR) routine care extension to 52w (in #PMRGCAJC one big qu asked was ?sustained benefit) sustained benefit (RR 2.5 GC-free remission) steroid-sparing (PNL 1.6g v 2.3g) & ritux ?cheap enough now but COVID calculus difficult POS0269 #EULAR2022 @RheumNow https://t.co/Ln2ArclKO8 https://t.co/OtCwdjIPeL